0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > BCMA

BCMA

BCMA Molecule Information

Name:B-cell maturation protein
Target Synonym:Tumor necrosis factor receptor superfamily member 17;B-cell maturation protein;CD_antigen: CD269;BCMA;TNFRSF17;BCM
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:28
Lastest Research Phase:Phase ?

BCMA Part of Bioactivity data

BCA-HF2H1-Cell-based assay
Evaluation of CAR expression

293 cells were transfected with anti-BCMA-scFv and RFP tag. 2e5 of the cells were stained with B. FITC-Labeled Human BCMA, His Tag (Cat. No. BCA-HF2H1, 1 µg/ml) and C. FITC-labeled protein control. A. Non-transfected 293 cells and C. FITC-labeled protein control were used as negative control. RFP was used to evaluate CAR (anti-BCMA-scFv) expression and FITC was used to evaluate the binding activity of FITC-Labeled Human BCMA, His Tag (Cat. No. BCA-HF2H1) (QC tested).

BCA-M43-SPR
Human_FcRn_Heterodimer_Protein_SPR

Anti-BCMA Neutralizing Antibody, Mouse IgG1 (Clone: AM43, Cat. No. BCA-M43) captured on CM5 chip via anti-mouse antibodies surface can bind Human BCMA, His Tag (Cat. No. BCA-H522y) with an affinity constant of 0.388 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

BCA-H522y-SPR
Human_FcRn_Heterodimer_Protein_SPR

Anti-Human BCMA MAb (human IgG1) captured on CM5 chip via Anti-Human IgG Fc antibodies surface, can bind Human BCMA, His Tag (Cat. No. BCA-H522y) with an affinity constant of 32.3 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

BCMA Protein Product ListCompare or Buy

Cat. No. Species Product Description Structure Purity Feature
BCA-C82E5 Cynomolgus / Rhesus macaque Biotinylated Cynomolgus / Rhesus macaque BCMA / TNFRSF17 Protein, His,Avitag™
BCA-C82E5-structure
BCA-M43 Mouse Anti-BCMA Neutralizing Antibody, Mouse IgG1 (recommended for neutralizing assay)
BCA-M43-sds
BCA-M43-elisa_1
BCA-M43-elisa_2
MBS-K004 Human BCMA protein-coupled magnetic beads
BCA-HF2H1 Human FITC-Labeled Human BCMA / TNFRSF17 Protein, His Tag
BCA-HF2H1-structure
BCA-HF2H1-sds
BCA-H5253 Human Human BCMA / TNFRSF17 Protein, Mouse IgG2a Fc Tag, low endotoxin
BCA-H5253-structure
BCA-H5253-sds
BCA-H5253-elisa_1
BCA-M52H3 Mouse Mouse BCMA / TNFRSF17 Protein, His Tag
BCA-M52H3-structure
BCA-M52H3-sds
BCA-M52H3-elisa_1
BCA-H82E4 Human Biotinylated Human BCMA / TNFRSF17 Protein, His,Avitag™
BCA-H82E4-structure
BCA-H82E4-sds
BCA-H82E4-elisa_1
BCA-H5259 Human Human BCMA / TNFRSF17 Protein, Llama IgG2b Fc Tag, low endotoxin
BCA-H5259-structure
BCA-H5259-sds
BCA-H5259-elisa_1
BCA-C52H7 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque BCMA / TNFRSF17 Protein, His Tag
BCA-C52H7-structure
BCA-C52H7-sds
BCA-C52H7-elisa_1
BCA-M82F0 Mouse Biotinylated Mouse BCMA / TNFRSF17 Protein, Fc,Avitag™
BCA-M82F0-structure
BCA-M82F0-sds
BCA-M82F0-elisa_1
BCA-M5258 Mouse Mouse BCMA / TNFRSF17 Protein, Fc Tag
BCA-M5258-structure
BCA-M5258-sds
BCA-M5258-elisa_1
BCA-C5253 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque BCMA / TNFRSF17 Protein, Fc Tag
BCA-C5253-structure
BCA-C5253-sds
BCA-C5253-elisa_1
BCA-C82F4 Cynomolgus / Rhesus macaque Biotinylated Cynomolgus / Rhesus macaque BCMA / TNFRSF17 Protein, Fc,Avitag™
BCA-C82F4-structure
BCA-C82F4-sds
BCA-C82F4-elisa_1
BC7-H82F0 Human Biotinylated Human BCMA / TNFRSF17 Protein, Fc,Avitag™
BC7-H82F0-structure
BC7-H82F0-sds
BC7-H82F0-elisa_1
BCA-H522y Human Human BCMA / TNFRSF17 Protein,His Tag
BCA-H522y-structure
BCA-H522y-sds
BCA-H522y-elisa_1
BCA-H522y-elisa_2
BCA-HF254 Human FITC-Labeled Human BCMA / TNFRSF17 Protein, Fc Tag
BCA-HF254-structure
BCA-HF254-sds
BCA-HF254-elisa_1
BC7-H5254 Human Human BCMA / TNFRSF17 Protein, Fc Tag (HPLC verified)
BC7-H5254-structure
BC7-H5254-sds
BC7-H5254-hplc
BC7-H5254-elisa_1

BCMA Customer Reviews

BCMA Molecule Synonym Name

TNFRSF17,CD269,BCM,BCMA

BCMA Molecule Background

Tumor necrosis factor receptor superfamily member 17 (TNFRSF17) is also known as B-cell maturation protein (BCMA), CD antigen CD269, which is a member of the TNF-receptor superfamily. TNFRSF17 contains one TNFR-Cys repeat. TNFRSF17 is expressed in mature B-cells, but not in T-cells or monocytes. TNFRSF17 is receptor for TNFSF13B/BLyS/BAFF and TNFSF13/APRIL. TNFRSF17 promotes B-cell survival and plays a role in the regulation of humoral immunity. TNFRSF17 can activate NF-kappa-B and JNK.

BCMA References

BCMA Related Molecule

BCMA Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
BCMA/CD19 CAR-T cell therapy (The First Affiliated Hospital of Nanchang University) Phase Ⅰ The First Affiliated Hospital of Nanchang University Multiple myeloma (MM) Details
TNB-383B TNB-383B Phase Ⅰ Teneobio, Abbvie Multiple myeloma (MM) Details
Anti BCMA CART cell therapy (Shanghai YaKe Biotechnology) Phase Ⅰ Yake Biotechnology Multiple myeloma (MM) Details
LCAR-B38M cell product JNJ-4528; JNJ-68284528; LCAR-B38M, JNJ 4528 Phase Ⅲ Nanjing Chuanqi Biotech, Janssen Multiple myeloma (MM) Details
Anti-BCMA anti-CD38 bispecific chimeric antigen receptor T cell therapy (Shengyan Pharmaceutical Technology) Phase Ⅰ Wuhan Union Hospital, Shengyan Pharmaceutical Technology Multiple myeloma (MM) Details
BCMA-CART (PD-1 knockdown, Unicar-Therapy Bio-medicine Technology) IND Filing Unicar-Therapy Bio-medicine Technology Multiple myeloma (MM) Details
Belantamab mafodotin GSK-2857916 BLA Filing GlaxoSmithKline Multiple myeloma (MM) Details
Idecabtagene vicleucel bb-2121 BLA Filing bluebird bio, Celgene Multiple myeloma (MM) Details
BCMA-PD1 CAR T cell therapy (General Hospital of the People's Liberation Army) Phase Ⅱ General Hospital of the People's Liberation Army Multiple myeloma (MM) Details
GC-012F GC-012F Phase Ⅰ Gracell Biotechnology Multiple myeloma (MM) Details
CC-98633 CC-98633 Phase Ⅰ Celgene Multiple myeloma (MM) Details
CART-BCMA CART-BCMA; MTV-273,CART BCMA,MTV273 Phase Ⅰ University of Pennsylvania, Novartis Multiple myeloma (MM) Details
P-BCMA-101 P-BCMA-101 Phase Ⅱ Poseida Therapeutics Multiple myeloma (MM) Details
BCMA CAR-NK 92 cell therapy (Asclepius Technology Company Group) Phase Ⅱ Asclepius Technology Company Group Multiple myeloma (MM) Details
BCMA-CS1 cCAR T cell therapy (iCell Gene Therapeutics) Phase Ⅰ iCell Gene Therapeutics Multiple myeloma (MM) Details
Anti-BCMA CAR T-cell therapy (Arcellx) CART-ddBCMA Phase Ⅰ Arcellx Multiple myeloma (MM) Details
HPN-217 HPN-217 Phase Ⅱ Harpoon Therapeutics, Abbvie Multiple myeloma (MM) Details
CC-99712 CC-99712 Phase Ⅰ Celgene Multiple myeloma (MM) Details
Human BCMA chimeric antigen receptor autologous T cell(Nanjing Reindeer Medical Technology) CT103A Phase Ⅰ Innovent Biologics, Nanjing IASO Biotherapeutics Multiple myeloma (MM) Details
MEDI-2228 MEDI-2228,MEDI 2228,MEDI2228 Phase Ⅰ MedImmune Multiple myeloma (MM) Details
SEA-BCMA SEA-BCMA; SGN-BCMA Phase Ⅰ Seattle Genetics Multiple myeloma (MM) Details
PBCAR-269A PBCAR-269A Phase Ⅱ Precision BioSciences Multiple myeloma (MM) Details
Anti-BCMA CAR-T cell therapy (PersonGen Biomedicine) Phase Ⅰ PersonGen Biomedicine, Second Affiliated Hospital of Suzhou UniversitySecond Affiliated Hospital of Suzhou University Multiple myeloma (MM) Details
BCMA CAR-T Cells (Pregene) Phase Ⅰ Pregene Multiple myeloma (MM) Details
bb-21217 bb-21217,bb 21217,bb21217 Phase Ⅰ bluebird bio, Celgene Multiple myeloma (MM) Details
AMG-420 AMG-420; BI-836909 Phase Ⅰ Micromet, Boehringer Ingelheim, Amgen Multiple myeloma (MM) Details
CTX-120 CTX-120 Phase Ⅰ CRISPR Therapeutics Multiple myeloma (MM) Details
KITE-585 KITE-585,KITE585 Phase Ⅰ Kite Pharma, National Cancer Institute Multiple myeloma (MM) Details
REGN-5459 REGN-5459 Phase Ⅱ Regeneron Pharmaceutical Multiple myeloma (MM) Details
PF-06863135 PF-06863135,PF 06863135 Phase Ⅰ Pfizer Multiple myeloma (MM) Details
BCMA-CD19 cCAR T cell therapy (iCell Gene Therapeutics) Phase Ⅰ iCell Gene Therapeutics Multiple myeloma (MM), Lymphoma Details
LCAR-B4822M LCAR-B4822M,LCAR B4822M,LCARB4822M Phase Ⅰ GenScript Biotech Corporation Multiple myeloma (MM) Details
CAR-BCMA T cell therapy CT-053-CARsgen,CT053 Phase Ⅱ CARsgen Therapeutics Multiple myeloma (MM) Details
Anti BCMA CAR T cell therapy (Shanghai Hrain Biotechnology) BCMA-CART Phase Ⅰ Shanghai Hrain Biotechnology Multiple myeloma (MM) Details
JNJ-64007957 JNJ-7957; JNJ-64007957; JNJ-64007959 Phase Ⅰ Janssen, Genmab Multiple myeloma (MM) Details
BCMA CAR-T cell therapy (Chongqing Precision Biotech) Phase Ⅱ Chongqing Precision Biotech Plasma cell neoplasms, Multiple myeloma (MM) Details
AUTO-2 AUTO-2; SUB-96123,AUTO 2; SUB 96123 Phase Ⅱ Autolus Multiple myeloma (MM) Details
Anti BCMA chimeric antigen receptor T cell therapy (Chongqing Precision Biotech) Phase Ⅱ Chongqing Precision Biotech Multiple myeloma (MM) Details
CC-93269 CC-93269; EM-901 Phase Ⅰ Celgene Multiple myeloma (MM) Details
Autologous BCMA-directed CAR T-cell therapy (The First Affiliated Hospital of Soochow University) Phase Ⅲ The First Affiliated Hospital of Soochow University Multiple myeloma (MM) Details
ACTR 087/SEA BCMA combination therapy Phase Ⅰ Unum Therapeutics, Seattle Genetics Multiple myeloma (MM) Details
anti-BCMA CAR T-cell Therapy (Juno Therapeutics) ET-140; ET140-CAR; JCARH-125; FCARH-143; MCARH-171 Phase Ⅱ Juno Therapeutics Acute lymphoblastic leukaemia (ALL), Non-Hodgkin B-cell lymphomas Details
ALLO-715 ALLO-715 Phase Ⅰ Allogene Therapeutics, Cellectis Multiple myeloma (MM) Details
BCBM CAR T cell (Pregene) Phase Not Specified Pregene, BioCast Multiple myeloma (MM) Details

This web search service is supported by Google Inc.

totop